MCSP-aligned scFv antibody fragments and use of same
Single-chain fragment variable (scFv) antibody fragment (I), directed against melanoma-associated chondroitin sulfate proteoglycan (MCSP), with variable domains in an orientation of heavy chain variable domain-linker-light chain variable domain (VH-linker-VL), is new, where the VH domain comprises a...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Single-chain fragment variable (scFv) antibody fragment (I), directed against melanoma-associated chondroitin sulfate proteoglycan (MCSP), with variable domains in an orientation of heavy chain variable domain-linker-light chain variable domain (VH-linker-VL), is new, where the VH domain comprises amino acid sequences of SEQ ID NO. 1 (comprising a fully defined 121 amino acid sequence, as given in the specification) or SEQ ID NO. 2 (comprising a fully defined 121 amino acid sequence, as given in the specification) and the linker is a covalent bond or an oligopeptide. Single-chain fragment variable (scFv) antibody fragment (I), directed against melanoma-associated chondroitin sulfate proteoglycan (MCSP), with variable domains in an orientation of heavy chain variable domain-linker-light chain variable domain (VH-linker-VL), is new, where the VH domain comprises amino acid sequences of SEQ ID NO. 1 (comprising a fully defined 121 amino acid sequence, as given in the specification) or SEQ ID NO. 2 (comprising a fully defined 121 amino acid sequence, as given in the specification), the VL domain comprises amino acid sequences of SEQ ID NO. 3 (comprising a fully defined 112 amino acid sequence, as given in the specification) or SEQ ID NO. 4 (comprising a fully defined 112 amino acid sequence, as given in the specification) or corresponding sequences exhibiting one or more point mutations, and the linker is a covalent bond or an oligopeptide. Independent claims are included for: (1) a fusion protein comprising (i) a domain with (I) and (ii) at least a domain with a functional protein- or peptide sequence that is covalently linked with the domain (i); (2) nucleic acid sequences for (I) or the fusion protein; (3) a vector comprising the nucleic acid sequences; and (4) a cell comprising (I), fusion protein, the vector and/or the nucleic acid sequences. ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
Die Erfindung betrifft gegen das Melanom-assoziierte Chondroitinsulfat Proteoglykan (MCSP)-gerichtete scFv-Antikörperfragmente mit spezifischer Anordnung der variablen Domänen und spezielle Fusionsproteine dieser scFv-Fragmente, deren Herstellung und Verwendung zur behandlung von Tumorerkrankungen. |
---|